Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial)

PHASE3CompletedINTERVENTIONAL

Enrollment

173

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions

Saphenous Vein Graft Disease

Interventions

DRUG

Atorvastatin 80 mg daily

Atorvastatin 80 mg daily for 1 year

DRUG

Atorvastatin 10 mg daily

Atorvastatin 10 mg daily for 1 year

Trial Locations (2)

Lynn Heart and Vascular Institute, Boca Raton Regional Hospital, Boca Raton

University of Ottawa Heart Institute, Ottawa